- Home
- People
- R&D
CUV151 DNA Repair Study Update
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the recent results from the CUV151 study, looking at whether afamelanotide can reduce and repair photodamage (skin damage induced by ultraviolet radiation) in healthy volunteers.R&DDr Pilar Bilbao — CLINUVEL’s DNA Repair Program
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.R&DCLINUVEL: developing innovative treatments for stroke patients
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.CLINUVEL newsNasdaq TradeTalks Interview
CLINUVEL’s Managing Director, Dr Philippe Wolgen, speaks with Jill Malandrino on Nasdaq TradeTalks, 26 October 2021.
- R&D
- R&D
CUV151 DNA Repair Study Update
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the recent results from the CUV151 study, looking at whether afamelanotide can reduce and repair photodamage (skin damage induced by ultraviolet radiation) in healthy volunteers.R&DDr Pilar Bilbao — CLINUVEL’s DNA Repair Program
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.R&DCLINUVEL: developing innovative treatments for stroke patients
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.R&DDr Pilar Bilbao – Update on CLINUVEL’s Stroke Program
In January 2022, CLINUVEL announced that it had completed enrolment in its world-first study of afamelanotide as a treatment for arterial...
- Publications
- Publications
The Weekend Effect – A Worrying Truth or Myth?
Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...PublicationsIs skin cancer in your job description?
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...PublicationsTomatoes and carrots… photoprotection from within?
Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...R&DHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Finance & investing
- CLINUVEL news
CLINUVEL – update on EPP treatment in England
CLINUVEL’s Director of Global Operations, Mr Lachlan Hay, provides an update on erythropoietic protoporphyria (EPP) patient treatment in England and the Company’s next steps.CLINUVEL newsCLINUVEL Operational Update
In a webcast released today, CLINUVEL’s Director of Global Operations, Lachlan Hay, provides insights on the Company’s Investor Relations programme, the launch of its first polychromatic screen and the use of SCENESSE® in Europe and the USA.CLINUVEL newsCLINUVEL PHARMACEUTICALS LTD Annual General Meeting 2022
On October 26th 2022 CLINUVEL PHARMACEUTICALS held its 2022 Annual General MeetingCLINUVEL newsCLINUVEL Investor Webinar on FY2022 financial results
In an investor and analyst webinar hosted by CLINUVEL, Mr Malcolm Bull, Head of Investor Relations, is joined by Mr Darren Keamy, Chief Financial Officer, and Dr Philippe Wolgen, Managing Director, in discussing the financial results for the year ended 30 June 2022 and the Company’s plans for FY2023 and beyond.